These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31486963)

  • 1. Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels.
    Ebied AM; Li T; Axelrod SF; Tam DJ; Chen Y
    J Thromb Thrombolysis; 2020 Feb; 49(2):206-213. PubMed ID: 31486963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency Department Management of Acute Venous Thromboembolism in Patients With Obesity With Intravenous Unfractionated Heparin and Anti-Xa Monitoring.
    Tyler DJ; Caruso KA; Lyden AE; Karpowitsch KM
    J Pharm Pract; 2023 Jun; 36(3):588-593. PubMed ID: 35113739
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients.
    Isherwood M; Murphy ML; Bingham AL; Siemianowski LA; Hunter K; Hollands JM
    J Thromb Thrombolysis; 2017 May; 43(4):476-483. PubMed ID: 28070821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
    Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
    Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
    Levito MN; Coons JC; Verrico MM; Szymkowiak A; Legler B; Dueweke EJ; Kane-Gill SL
    Ann Pharmacother; 2021 May; 55(5):618-623. PubMed ID: 32885997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
    Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
    J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life.
    Heizer JW; Schardt TQ; Murphy ME; Branchford BR
    Thromb Res; 2019 May; 177():17-22. PubMed ID: 30844684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of weight-based dosing of unfractionated heparin in obese children.
    Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL
    J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
    Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
    J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
    Clark NP; Delate T; Cleary SJ; Witt DM
    Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.
    Bauer SR; Ou NN; Dreesman BJ; Armon JJ; Anderson JA; Cha SS; Oyen LJ
    Mayo Clin Proc; 2009 Dec; 84(12):1073-8. PubMed ID: 19955244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
    Frugé KS; Lee YR
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Intraprocedural Unfractionated Heparin Protocol During Catheter Ablation of Atrial Fibrillation in the Presence of Direct Oral Anticoagulants and Wide Spectrum of Body Mass Index.
    Safani M; Tobias S; Shandling AH; Redmond K; Lee MY
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):349-358. PubMed ID: 33749350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
    Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
    Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
    Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
    Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
    Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
    Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.